Get the Stockscreener App
1.11
4.70%
-0.06
Caribou Biosciences Inc stock is traded at $1.11, with a volume of 756.68K.
It is down -4.70% in the last 24 hours and down -18.61% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
See More
Previous Close:
$1.17
Open:
$1.15
24h Volume:
756.68K
Relative Volume:
0.54
Market Cap:
$102.78M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-0.7603
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-12.89%
1M Performance:
-18.61%
6M Performance:
-43.69%
1Y Performance:
-85.69%
1-Day Range:
$1.11
$1.17
1-Week Range:
$1.11
$1.28
52-Week Range:
$1.11
$7.93
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.115 | 102.78M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.02 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.15 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.08 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.19 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on Monday - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus PT from Analysts - Defense World
Institutional investors may adopt severe steps after Caribou Biosciences, Inc.'s (NASDAQ:CRBU) latest 13% drop adds to a year losses - Simply Wall St
Caribou Biosciences stock hits 52-week low at $1.22 - Investing.com
Caribou Biosciences stock hits 52-week low at $1.22 By Investing.com - Investing.com UK
Caribou Biosciences, Inc. (NASDAQ:CRBU) is a favorite amongst institutional investors who own 62% - Yahoo Finance
Caribou Biosciences, Inc. Investors: Please contact the - GlobeNewswire
Caribou Biosciences, Inc. (NASDAQ: CRBU) Investor Alert: Deadline in Lawsuit on February 24, 2025 - openPR
2025-02-24 | Caribou Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc. - EIN News
Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your RightsCRBU - PR Newswire
Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU - ACCESS Newswire
2025-02-23 | INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences | NDAQ:CRBU | Press Release - Stockhouse Publishing
Faruqi & Faruqi Reminds Caribou Biosciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025CRBU - PR Newswire
CRBU DEADLINE NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, - GlobeNewswire
CRBU DEADLINE NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 24 Deadline in Securities Class Action – CRBU - GlobeNewswire Inc.
Caribou Biosciences chief scientific officer sells $4,811 in stock By Investing.com - Investing.com Canada
Caribou Biosciences chief legal officer sells shares worth $4,811 By Investing.com - Investing.com South Africa
Caribou Biosciences chief business officer sells shares for $4,811 - Investing.com India
2025-02-21 | Class Action Filed Against Caribou Biosciences, Inc. (CRBU)February 24, 2025 Deadline to JoinContact Levi & Korsinsky | NDAQ:CRBU | Press Release - Stockhouse Publishing
Shareholders that lost money on Caribou Biosciences, - GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - Newsfile
Lost Money on Caribou Biosciences, Inc.(CRBU)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse Publishing
2025-02-20 | Levi & Korsinsky Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025CRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU - TradingView
2025-02-20 | Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
Caribou Biosciences, Inc. Class Action: The Gross Law Firm Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 24, 2025CRBU - Morningstar
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GlobeNewswire
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit - PR Newswire
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
CRBU DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors ... - The Bakersfield Californian
Caribou Biosciences Gets Court Nod for IPO Investor Deal (2) - Bloomberg Law
Levi & Korsinsky Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineCRBU - Stockhouse Publishing
Caribou Biosciences Faces Lawsuit Amid Stock Decline and Clinical Trial Concerns - PUNE.NEWS
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse Publishing
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - Markets Insider
2025-02-18 | Investors who lost money on Caribou Biosciences, Inc.(CRBU) should contact Levi & Korsinsky about pending Class ActionCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Caribou Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesCRBU - PR Newswire
Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Caribou Biosciences, Inc. Sued for Securities Law - GlobeNewswire
Caribou Biosciences Inc (NASDAQ: CRBU) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register
2025-02-18 | Caribou Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
CRBU Lawsuit Alert! Class Action Against Caribou Biosciences Inc. - TipRanks
Exclusive: Caribou's CEO Reveals CRISPR Innovation Strategy at Two Elite Investor Events - StockTitan
Next Generation Genome Editing Market Top Companies Study - openPR
2025-02-17 | Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc. (CRBU) Shareholders | NDAQ:CRBU | Press Release - Stockhouse Publishing
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - StreetInsider.com
2025-02-16 | Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
CRBU IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Caribou Biosciences, Inc. - The Bakersfield Californian
CRBU IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, - GlobeNewswire
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Caribou Biosciences Inc Stock (CRBU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khan Ruhi Ahmad | Chief Business Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
66,936 |
| Kanner Steven | Chief Scientific Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
431,556 |
| Ryali Sriram | Chief Financial Officer |
Jan 29 '25 |
Buy |
1.42 |
17,360 |
24,651 |
17,360 |
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):